Oxford Endovascular secures £8 million to take novel brain aneurysm tech to human trials
Parkwalk Advisors led the latest funding round investing £4.2 million alongside Norcliffe Capital, The University of Oxford, Oxford Science Enterprises (OSE) and Vulpes Investment Management.
Oxford Endovascular today announces the successful completion of an 8 million GBP Series A+ funding round. The MedTech start-up, founded in 2015, is developing a novel approach to preventing brain haemorrhage by treating intracranial aneurysms. Led by Parkwalk Advisors, the UK’s leading investor in university spinouts, this latest investment will help take its medical device, OXIFLOW, a step closer to a First-In-Human clinical study. The market opportunity for devices used to treat brain aneurysms is approaching 3 billion USD per year.
